

THE TEXTBOOK OF

Pharmaceutical Medicine

7TH EDITION

EDITED BY

John P. Griffin, John Posner
and Geoffrey R. Barker

 WILEY-BLACKWELL

BMJ|Books

Table of Contents

[Title page](#)

[Copyright page](#)

[Contributors](#)

[The editors](#)

[Acknowledgements](#)

[List of abbreviations](#)

[Preface](#)

[Part I: Research and development](#)

[1 Discovery of new medicines](#)

[Introduction](#)

[Medicines marketed in the years 2008-2011](#)

[Impact of high throughput screening in drug discovery](#)

[Impact of combinatorial chemistry on drug discovery](#)

[Fragment-based design](#)

[Examples in drug discovery](#)

[Oligonucleotide-based therapeutics](#)

Recent drug discovery strategies to improve success

Drug repositioning

The new role of academia in pharmaceuticals

Conclusions

2 Pharmaceutical development

Introduction

Drug delivery

Product formulation types

Quality by Design

Drug substance properties at the preclinical testing stage

Principles of pharmaceutical development

Oral solid dosage form development

Sterile products

Conclusions

3 Preclinical safety testing

Introduction

Preclinical safety pharmacology

Single-dose studies

Repeat-dose studies

Carcinogenicity studies

Reproductive toxicology

Genotoxicity testing

Irritation and sensitisation testing

Specific considerations for biologicals

Animal numbers, costs and ethics

4 Exploratory development

Introduction

Planning exploratory development

Requirements for administration of an NME to humans

Preparation for the first administration to humans

Studies in healthy volunteers

Objectives of first-in-human studies

Design of the first-in-human study

Minimising risk

Subsequent studies in exploratory development

Outcomes of ED

5 Clinical pharmacokinetics

Introduction

Basic concepts

Bioavailability and bioequivalence

Drug interactions

The elderly

Renal impairment

Liver disease

Disposition, rates and routes of elimination of radiolabelled drug

Pharmacokinetic-pharmacodynamic modelling

Population analysis

The rest of the typical clinical pharmacokinetics package

The ideal drug from the point of view of pharmacokinetics

Role of pharmacokinetic properties in
determining a dosage regimen
Conclusions

6 Biological therapeutics

Introduction - the history of biologics
development
Differences between 'chemical' and 'biological'
molecules
Immunogenicity
First-in-human dose selection for a biologic
Conclusions

7 Objectives and design of clinical trials

History of the controlled clinical trial
Objectives of clinical trials in drug development
Design of controlled clinical trials
Analysis of controlled clinical trials
Final word

8 Conduct of clinical trials: Good Clinical Practice

Introduction
Good Clinical Practice
Preparation of documentation for the clinical trial
The IMP and its documents
Running the clinical trial
Preparation of the clinical report
Quality management

Conclusions

9 Medical statistics

Introduction

Probability

Scales of measurement and clinical endpoints

Basic statistical principles

Issues in design

Meta-analysis and summaries

10 Development of medicines: full development

Introduction

Taking products into later development phase

Preparing the plan

The detailed clinical development plan

Executing the plan

Acknowledgements

11 Pharmacovigilance

Introduction

Legislation and the regulatory authorities

Safety governance

Case handling, expedited and periodic reporting

Signal detection and signal evaluation

Benefit-risk evaluation

Labelling and risk management planning

12 Vaccines

Vaccines: history, controversies and public health issues

Vaccine clinical trials

Vaccine safety monitoring

Vaccinology ethics

Importance of vaccine manufacturing and supply

The future of vaccinology

13 Drugs for cancer

Introduction

Biology of cancer

Rationally designed therapies

Pharmacogenetics, pharmacogenomics and patient selection for treatment

Resistance mechanisms

Cancer drug discovery and preclinical development

Clinical trials in oncology

Current issues in oncology clinical drug development

Conclusions and future perspectives

14 Ethics of human experimentation

Introduction

Principles of ethical biomedical research

History

Informed consent

Children in research

Adults unable to give consent

Who should seek consent?
Research Ethics Committees
Assessment of risk
Conclusions

15 Drug development in paediatrics and neonatology

History and milestones of paediatric drug development
Need for clinical drug studies in paediatrics
Developmental pharmacology – differences between adults, children and neonates and implications for research
Difficulties of performing clinical trials in children
Ethical considerations for paediatric clinical drug trials
Regulatory requirements
Conclusions

16 Due diligence and the role of the pharmaceutical physician

Introduction
Role of the pharmaceutical physician
Scope of due diligence
Process of due diligence
Writing and assembling the due diligence report
Due diligence in private equity and life science transactions
Conclusions

Part II: Regulation

17 A history of drug regulation in the UK

Introduction

The thalidomide disaster and its immediate aftermath

Voluntary controls in the UK (1963-1971)

Voluntary adverse reaction reporting system: Yellow Card scheme

Manufacturers' licences and Good Manufacturing Practice

Wholesale dealers' licences

General safety measures

Scrutiny of functioning of the Medicines Division and the establishment of the Medicines Control Agency

Medicines and Healthcare products Regulatory Agency

European dimensions

International dimensions

Conclusions

Update

18 The Clinical Trials Directive

Introduction

History of the Clinical Trials Directive

Scope and content of the clinical trials and GCP Directives

Protection of vulnerable subjects in clinical trials

[Clinical trials guidelines](#)

[EU databases](#)

[Clinical trials and marketing authorisations](#)

[Inspections of clinical trials](#)

[Clinical Trials Facilitation Group](#)

[Revision of the clinical trials legislation](#)

[19 Human medicinal products in the European Union: Regulations, Directives and structures](#)

[Introduction](#)

[Overview of the European Union](#)

[European pharmaceutical legislation](#)

[European Medicines Agency](#)

[International harmonisation](#)

[20 Human medicinal products in the European Union: Procedures](#)

[Applications for marketing authorisations](#)

[Centralised applications](#)

[National applications](#)

[Application for change in classification of supply](#)

[Application for orphan medicine designation](#)

[Application for Paediatric Investigation Plan or waiver](#)

[Applications for scientific advice and protocol assistance](#)

[Application for registration of herbal medicinal products](#)

[Applications for clinical trials authorisation](#)
[Post-approval variations to marketing authorisations](#)
[European Union referrals to CHMP](#)
[Product literature, promotion and advertising](#)
[Pharmacovigilance](#)
[Wholesale distribution, pricing and reimbursement](#)

[21 European regulation of medical devices](#)

[Introduction](#)
[Law on specific devices](#)
[Resolution of uncertainties](#)
[Competent authorities and notified bodies](#)
[What is a medical device?](#)
[The drug-device borderline](#)
[Drug-device combinations](#)
[Classification of devices](#)
[Conformity assessment procedures and CE marking](#)
[Registration](#)
[Harmonised standards](#)
[Custom-made devices](#)
[Systems and procedure packs](#)
[Reprocessing](#)
[Essential requirements](#)
[Information supplied by the manufacturer](#)
[Who is a manufacturer?](#)
[Manufacturers outside the EEA](#)

['Placing on the market' and 'putting into service'](#)

[Clinical investigation](#)

[*In vitro* diagnostics](#)

[Advanced therapy medicinal products](#)

[Adverse event reporting: vigilance](#)

[General product safety Directive](#)

[Recall](#)

[Enforcement and sanctions](#)

[22 Paediatric regulation](#)

[Introduction](#)

[Case study](#)

[Paediatric population in the European Union](#)

[New paediatric medicines Regulation](#)

[Aims and objectives of the Regulation](#)

[Other tasks of the European Medicines Agency](#)

[Ethical aspects of studies in children](#)

[Summary and outlook](#)

[23 Technical requirements for registration of pharmaceuticals for human use: The ICH process](#)

[Introduction](#)

[ICH organisation \(1990-2003\)](#)

[The ICH process](#)

[ICH 5 Meeting Report](#)

[The CTD post-ICH 5](#)

[ICH 6: November 2003, Osaka](#)

[ICH organisation \(2003-2007\)](#)

[ICH organisation: \(2007-2011\) and press releases](#)
[Revised ICH Terms of Reference \[16\]](#)
[Conclusions to date](#)

[24 The regulation of drug products by the US Food and Drug Administration](#)

[Introduction](#)
[Regulatory framework](#)
[FDA history](#)
[Historical overview of drug regulation statutes](#)
[Other pharmaceutical products](#)
[Two classes of drug products](#)
[Regulation of non-prescription drugs](#)
[Regulation of prescription drugs](#)
[Biological drugs](#)
[Enforcement](#)
[Conclusions](#)

[25 The US FDA in the drug development, evaluation and approval process](#)

[Introduction](#)
[Investigational new drug application](#)
[New drug application \(NDA or BLA\)](#)
[Conclusions](#)

[26 Future prospects of the pharmaceutical industry and its regulation in the USA](#)

[Introduction](#)

[Wider aspects of the evolution of the FDA and the pharmaceutical industry from 1962 to 2012](#)
[Summary of changing environment and impact on industry](#)
[Improvements needed for the future](#)
[Conclusions](#)

[27 Regulatory and clinical trial systems in Japan](#)

[Introduction](#)
[Governing law](#)
[The Japanese regulatory system](#)
[Clinical trial systems](#)
[Conclusions](#)

[28 The regulation of therapeutic products in Australia](#)

[Introduction](#)
[History of prescription medicine regulation](#)
[TGA registration](#)
[Listing on the pharmaceutical benefits scheme - the 'fourth hurdle'](#)
[Access to medicines not registered or listed on the ARTG](#)
[Presentation](#)
[Patents](#)
[Non-prescription medicines and complementary medicines](#)
[Medical devices](#)

Part III: Health care marketplace

29 An Introduction to life cycle management of medicines

Introduction

The life cycle management team and the importance of value

Life cycle strategies

Second generation or reformulation of products

Fixed-dose combinations

Indication expansion

Generic investment

Prescription to over-the-counter products

Divestiture

Conclusions

30 Availability of medicines online and counterfeit medicines

Introduction

Definitions of counterfeit, illegally diverted, falsified and substandard drugs

History

Scale of the problem

Three study cases

Actions undertaken to counteract counterfeit drugs

31 The supply of unlicensed medicines for individual patient use

[Introduction](#)

[EU law](#)

[UK law](#)

[Particular issues relating to supply of unlicensed medicines](#)

[Product liability issues](#)

[Professional guidance](#)

[Review of the regulatory framework by the MHRA](#)

[Conclusions](#)

[32 Legal and ethical issues relating to medicinal products](#)

[Introduction](#)

[Chronology of production, development and marketing](#)

[Contractual arrangements in clinical research](#)

[Post-authorisation – controls and protection of investment](#)

[33 Medical marketing](#)

[Introduction](#)

[Pharmaceutical market](#)

[Strategic planning](#)

[Customers](#)

[Market research and market intelligence](#)

[Promotion](#)

[Medical information](#)

[Brands](#)

[Patients](#)

[Franchises](#)

[Patent expiry and generics](#)

[Demonstrating the benefits of medicine](#)

[National Institute for Health and Clinical Excellence](#)

[Conclusions](#)

[34 Information and promotion](#)

[Introduction](#)

[Legislation, controls and codes and their enforcement](#)

[The Medicines Regulations](#)

[Other relevant legislation](#)

[Vetting](#)

[Monitoring of published advertising material](#)

[Handling of complaints](#)

[Enforcement](#)

[Marketing, advertising and promotion of prescription medicines](#)

[Information](#)

[Procedural aspects relating to information and promotion](#)

[Editorial note](#)

[35 Economics of health care](#)

[Introduction](#)

[Economics of the National Health Service](#)

[Measuring the value](#)

[Compulsory economic evaluation: the ultimate measure](#)

Conclusions

36 Controls on NHS medicines prescribing and expenditure in the UK (a historical perspective) with some international comparisons

Introduction

NHS and Community Care Act 1990

Problem of the rising NHS medicines bill

Prescription charges for NHS medicines

Pharmaceutical Price Regulation Scheme

Office of Fair Trading report on PPRS and its consequences

2009 Pharmaceutical Price Regulation Scheme

Value-based pricing and the future of PPRS

The Drug Tariff and reference pricing

Contract purchase of medicines from cheap sources

The MacGregor Committee

Generic substitution

Enforced price reductions

Limited or selected lists

Indicative prescribing scheme and GP fundholding

Development of primary care groups

Changing the legal status of medicines from prescription only to over-the-counter availability

Encouragement to prescribe generically

[National Institute for Health and Clinical Excellence](#)
[European Transparency Directive](#)
[Supply of controlled drugs](#)
[British National Formulary](#)
[International comparisons](#)
[Conclusions and future steps within the UK NHS](#)

[37 Pharmaceutical medicine in the emerging markets](#)

[Introduction](#)
[What are 'emerging markets'?](#)
[The pharmaceutical market](#)
[Changing patterns of pharmaceutical medicine](#)
[Late clinical development](#)
[Regulations](#)
[Commercialisation of medicines](#)
[Development of medicines for the diseases of the developing world](#)
[The future: re-engineering R&D through emerging markets](#)
[Acknowledgement](#)

[38 Biosimilars](#)

[Introduction](#)
[Biosimilars in Europe](#)
[Biosimilars in the USA](#)
[Biosimilars in other regions](#)
[The future](#)

Appendix 1 Declaration of Helsinki

World Medical Association Declaration of Helsinki

Appendix 2 Agreements and Guidelines for Implementation of Clinical Trials

2.1 Clinical trial agreement for pharmaceutical industry sponsored research in NHS Trusts

1 Definitions

2 Site Principal Investigator

3 Clinical Trial Governance

4 Obligations of the Parties

5 Liabilities and indemnity

6 Confidentiality

7 Publicity

8 Publication

9 Intellectual Property

10 Financial arrangements

11 Term

12 Early termination

13 Relationship between the Parties

14 Agreement and modification

15 Force majeure

16 Notices

17 Rights of Third Parties

18 Waiver

19 Dispute resolution

20 Governing law

2.2 ABPI form of Indemnity for Clinical Studies

2.3 ABPI Guideline on Advertising for Subjects for Clinical Trials

1 Essential Information for an Advertisement

2 Additional Permitted Content

3 Statements That Should Not Be Used

2.4 Guidelines for company-sponsored Safety Assessment of Marketed Medicines (SAMM)

Introduction

Scope of guidelines

1 Definition of Safety Assessment of Marketed Medicines

2 Scope and objectives of SAMM

3 Design of studies

4 Conduct of studies

5 Liaison with regulatory authorities

6 Promotion of medicines

7 Doctor participation

8 Ethical issues

9 Procedure for complaints

10 Review of Guidelines

Appendix 3 Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001

The European Parliament and the Council of the European Union

Have adopted this directive

Appendix 4 PharmaTrain Syllabus 2010

- [1 Discovery of Medicines](#)
- [2 Development of Medicines: Planning](#)
- [3 Non-Clinical Testing](#)
- [4 Pharmaceutical Development](#)
- [5 Exploratory Development \(Molecule to Proof-of-Concept\)](#)
- [6 Confirmatory Development: Strategies](#)
- [7 Clinical Trials](#)
- [8 Ethics and Legal Issues](#)
- [9 Data Management and Statistics](#)
- [10 Regulatory Affairs](#)
- [11 Drug Safety, Pharmacovigilance and Pharmacoeconomics](#)
- [12 Information, Promotion and Education](#)
- [13 Economics of Health Care](#)
- [14 Therapeutics](#)

[Index](#)

The Textbook of Pharmaceutical Medicine

EDITED BY

John P. Griffin

BSc, PhD, MBBS, FRCP, FRCPath, FFPM
Director, Asklepieion Consultancy Ltd;
Visiting Professor, University of Surrey Postgraduate Medical School;
Former Director, ABPI;
Formerly Professional Head of the Medicines Division, DOH (now MHRA), London, UK

John Posner

BSc, PhD, MBBS, FRCP, FFPM
Independent Consultant in Pharmaceutical Medicine
John Posner Consulting
Beckenham, Kent, UK;
Visiting Professor, School of Biomedical Sciences, King's College London, UK

Geoffrey R. Barker

TD, BSc, MSc, MBBS, FDSRCS, FRCS, FFPM
Independent Consultant in Pharmaceutical Medicine
Limited Partner, Pappas Ventures, NC, USA;
Board Member, Trustee and Registrar Faculty of Pharmaceutical Medicine of The Royal Colleges of Physicians UK
Former Adj. Professor Immunology, Duke University Medical Center, NC, USA
Formerly Chief Medical and Scientific Officer, Quintiles Transnational Corp, NC, USA

7TH EDITION

 **WILEY-BLACKWELL**
A John Wiley & Sons, Ltd., Publication

BMJ|Books

This edition first published 2013, © 2013 by John Wiley & Sons, Ltd; 1993, 1994, 1998 © The Queen's University Belfast; 2002, 2006, 2009 © Blackwell Publishing Ltd

BMJ Books is an imprint of BMJ Publishing Group Limited, used under licence by Blackwell Publishing which was acquired by John Wiley & Sons in February 2007. Blackwell's publishing programme has been merged with Wiley's global Scientific, Technical and Medical business to form Wiley-Blackwell.

Registered office: John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial offices: 9600 Garsington Road, Oxford, OX4 2DQ, UK

The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell

The right of the authors to be identified as the authors of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names,

service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was

written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication Data

The textbook of pharmaceutical medicine / edited by John P. Griffin, John Posner, Geoffrey R. Barker. – 7th ed.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-0-470-65987-8 (cloth : alk. paper)

I. Griffin, J. P. (John Parry) II. Posner, John. III. Barker, Geoffrey R.

[DNLM: 1. Drug Approval. 2. Clinical Trials as Topic. 3. Pharmacology. QV 771]

615.1-dc23

2012037180

A catalogue record for this book is available from the British Library.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Cover design by Sarah Dickinson

Contributors

Denis V. Azzopardi, F MedSci

Professor of Neonatal Medicine
Institute of Clinical Sciences
Imperial College London
London, UK

Geoffrey R. Barker, TD, BSc, MSc, MBBS, FDSRCS, FRCS, FFPM

Independent Consultant in Pharmaceutical Medicine
Limited Partner, Pappas Ventures, NC, USA;
Board Member, Trustee and Registrar Faculty of
Pharmaceutical Medicine of The Royal Colleges of Physicians
UK
Former Adj. Professor Immunology, Duke University Medical
Center, NC, USA
Formerly Chief Medical and Scientific Officer, Quintiles
Transnational Corp, NC, USA

Jane Barrett, MBBS, FFPM, LLM

The Barrett Consultancy
Gawsworth, Cheshire, UK

John Beadle, MBBCh, MBA

Chief Executive Officer,
PsiOxus Therapeutics Limited
Abingdon, Oxfordshire, UK

Nick Beckett, BSc (Hons)

Partner, CMS Cameron McKenna LLP
London, UK

Carole A. Bradley, MSc

Boehringer Ingelheim Canada Ltd
Burlington, ON, Canada

Paul Cummings, BSc(Hons), CBiol, FSB, EurProBiol, FRI

Director of Pharmaceutical Development
Pharmaceutical Development Services Ltd
Nottingham, UK

Kate L.R. Darwin, BA, DPhil, MRQA, MICR, CSci

Hammersmith Medicines Research Ltd
London, UK

Johann De Bono, MBChB, MSc, PhD, FRCP, FMedSci

Professor of Experimental Cancer Medicine
Drug Development Unit
Institute of Cancer Research;
Honorary Consultant Medical Oncologist
Royal Marsden NHS Foundation Trust
Sutton, UK

Elizabeth de Somer, BN, MMedSc

Director, Health Policy & Research
Medicines Australia
Deakin, ACT, Australia

Charles De Wet, MBChB, MPharMed, FFPM, FloD

Medical Director
UK and Ireland
Boehringer Ingelheim Ltd
Bracknell, UK

Ruth Diazaraque, MD, PhD, MBA, MSc Research Method, MSc Pharm Med

Sr Director Medical Affairs
Gilead Sciences Ltd
Uxbridge, UK

Ian Dodds-Smith, MA (Cantab)
Partner, Arnold & Porter (UK) LLP
London, UK

David B. Galloway, MB, ChB, DRCOG, FRCP, FRCPE, FFPM
Medical & Scientific Director
Cytosystems Ltd
Aberdeen, Scotland

Michael Gamlen, BSc, PhD, MRPharmS, FRSC
Managing Director
Pharmaceutical Development Services Ltd
Nottingham, UK

David Gillen, BSc, MRCGP, FFPM
Senior Director
Head of Medical Affairs
Celgene UK and Ireland
London, UK

Andrew P. Grieve, BSc, MSc, PhD, DSc
Senior Vice President Clinical Trials Methodology
Aptiv Solutions GmbH
Cologne, Germany

Jane R. Griffin, BA(Hons), MSc
Director, Market Access, Pricing and Outcomes Research
Boehringer Ingelheim Ltd
Bracknell, Berkshire, UK

John P. Griffin, BSc, PhD, MBBS, FRCP, FRCPATH, FFPM
Director, Asklepieion Consultancy Ltd;
Visiting Professor, University of Surrey Postgraduate Medical
School;
Former Director, ABPI;
Formerly Professional Head of the Medicines Division, DOH
(now MHRA), London, UK

Sarah Hanson, MA
Partner, CMS Cameron McKenna LLP
London, UK

Dean W.G. Harron, PhD, FRPharmS, MPSNI
School of Pharmacy
Queens University
Belfast, Northern Ireland

Judith Hirshorn, BSc (Hons), PhD, FAICD
Consultant
Rose Bay
NSW, Australia

Stephen F. Hobbiger, BSc, FRCP(E), FFPM
Vice President and European Qualified Person for
Pharmacovigilance
GlaxoSmithKline R&D
Stockley Park
Uxbridge, UK

Natsuko Hosoda
Medical & Regulatory Affairs
Quintiles Transnational Japan KK
Tokyo, Japan